Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $773.69M | $594.19M | $593.17M | $500.92M |
| Cost of revenue | $298.26M | $207.52M | $267.72M | $197.23M | $142.03M | $70.18M | $102.65M | $81.98M |
| Gross profit | $992.69M | $959.66M | $829.31M | $1.05B | $631.66M | $524.01M | $490.52M | $418.94M |
| Gross margin | 76.9% | 82.2% | 75.6% | 84.2% | 81.6% | 88.2% | 82.7% | 83.6% |
| Research and development | $413.13M | $364.87M | $372.22M | $358.81M | $323.62M | $265.12M | $300.17M | $270.93M |
| Selling, general and administrative | $347.92M | $322.55M | $325.37M | $322.08M | $323.31M | $239.95M | $295.34M | $220.99M |
| Operating expenses | $761.25M | $691.02M | $697.59M | $683.81M | $647.86M | $505.93M | $595.68M | $495.84M |
| Operating income | $231.44M | $268.64M | $131.72M | $367.98M | −$16.20M | $18.08M | −$105.16M | −$76.91M |
| Operating margin | 17.9% | 23.0% | 12.0% | 29.5% | -2.1% | 3.0% | -17.7% | -15.4% |
| EBITDA | $245.34M | $282.19M | $145.22M | $381.79M | −$2.26M | $32.48M | −$90.99M | −$62.92M |
| Interest income | $28.14M | $26.60M | $26.63M | $28.68M | $27.49M | $28.67M | $31.02M | $32.15M |
| Interest expense | −$82.05M | −$69.29M | −$129.34M | −$44.40M | −$61.46M | −$58.31M | −$38.97M | −$34.38M |
| Income before taxes | $177.81M | $221.65M | $161.14M | $238.97M | −$41.31M | −$2.37M | −$193.96M | −$108.66M |
| Income taxes | $13.31M | $15.66M | −$25.28M | −$12.12M | $30.92M | $15.88M | −$110.20M | $2.91M |
| Net income | $164.49M | $205.99M | $186.42M | $251.08M | −$72.23M | −$18.25M | −$83.76M | −$111.57M |
| Net margin | 12.7% | 17.6% | 17.0% | 20.1% | -9.3% | -3.1% | -14.1% | -22.3% |
| EPS, basic | $1.23 | $1.55 | $1.41 | $1.91 | −$0.55 | −$0.14 | −$0.65 | −$0.87 |
| EPS, diluted | $1.21 | $1.51 | $1.32 | $1.84 | −$0.55 | −$0.14 | −$0.65 | −$0.87 |
| Diluted shares | 138.28M | 138.23M | 141.08M | 137.35M | 130.63M | 129.68M | 129.14M | 128.59M |
Figures describe Alnylam Pharmaceuticals shares, not any token. As of Jul 30, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.